As seen above, PARP inhibition may be an intriguing issue: PARP1 was evaluated in 124 TGCT patients tumor specimens and overexpression was observed in Intratubular Germ Cell Carcinoma (100% of samples exhibited PARP1 overexpression), seminona (52.6%), EC (47.0%), yolk sac tumor (33.3%), teratoma (26.7%), and choriocarcinoma (25.0%), compared to 1.9% of normal testis specimens, showing no association between PARP1 expression and clinical variables [62]. The gene discussed is PARP1; the disease is choriocarcinoma.